Claims for Patent: 10,752,900

Summary for Patent: 10,752,900

Title:	Oligonucleotides for modulating gene expression and uses thereof
Abstract:	The present invention regards oligonucleotides for modulating the expression of a gene, in particular for modulating a gene responsible for a pathology of genetic, tumoural or viral origin. Moreover, the present invention relates to the use of said oligonucleotides, possibly chemically modified, for the treatment and/or the diagnosis of said diseases.
Inventor(s):	Tonelli; Roberto (Granarolo Emilia, IT), Venturelli; Leonardo (Calderara di Reno, IT), Tortori; Andrea (Citerna, IT), Montemurro; Luca (Bologna, IT)
Assignee:	BIOGENERA S.P.A. (Porretta Terme, IT)
Application Number:	16/009,303
Patent Claims:	1. A method of treating a tumor in a patient in need thereof with a composition comprising at least one single strand anti-gene oligonucleotide complementary to the anti-sense DNA strand of a target gene said target gene being selected from MYCN and MYC, said oligonucleotide comprising 6-30 nucleotides, and comprising a sequence comprising at least three groups of at least two consecutive guanines, said tumor being caused by an overexpression of said target gene, said method comprising administering to said patient in need an effective amount of said composition; inhibiting said target gene expression; and treating said patient. 2. The method according to claim 1, wherein said composition is in combination with a compound with pharmacological action selected from the group consisting of: NGF, somatostatin, retinoic acid, actinomycin D, asparaginase, bleomycin, busulphan capecitabine, carboplatin, cyclophosphamide, cyclosporine, cisplatin, cytarabine, clorambucil, dacarbazine, daunorubicin, docetaxel, doxorubicin hydrochloride, epirubicin hydrochloride, etoposide, fludarabine phosphate, fluorouracil, gemcitabine, idarubicin hydrochloride, hydroxyurea, ifophosphamide, irinotecan hydrochloride, melphalan, mercaptopurine, methotrexate, mitomycin, mitoxantrone, oxaliplatin, paclitaxel, procarbazine, raltitrexed, streptozocin, tegafururacil, temozolomide, thioguanine, thiotepe, topotecan, vinblastine, vincristine sulphate, vindesine and vinorelbine. 3. The method according to claim 1, wherein said tumor is an adult or pediatric tumor selected from the group consisting of: neuroblastoma, retinoblastoma, medulloblastoma, ependymoma, pheochromocytoma, embryonal carcinoma, germ cell tumour, alveolar rabdomyosarcoma, embryonal rabdomiosarcoma, Wilms tumor, clear cell sarcoma of the kidney, synovial sarcoma, hepatoblastoma, acute lymphoid leukaemia, chronic lymphoid leukaemia, acute lymphoblastic leukaemia, chronic lymphoblastic leukaemia, Burkitt's lymphoma, acute myeloid leukaemia, chronic myeloid leukaemia, acute megakaryoblastic leukaemia, B chronic lymphoid leukaemia, T-cell leukaemia, lymphomas, small cell lung cancer (microcytoma), lung adenocarcinoma, squamous cell lung carcinoma, typical and atypical primary lung cancer, large cell lung carcinoma, large-cell neuroendocrine lung carcinoma, glioblastoma, hepatocarcinoma, basal cell carcinoma, ovarian tumour, breast tumor and colon cancer. 4. The method according to claim 1, wherein the groups of at least two consecutive guanines are continuous with each other. 5. The method according to claim 1, wherein the groups of at least two consecutive guanines are spaced apart by at least one nucleotide, said nucleotide not being a guanine. 6. The method according to claim 1, wherein the groups of at least two consecutive guanines are at least four, five or six in number. 7. The method according to claim 1, wherein said oligonucleotide is conjugated with a carrier sequence at the 3' and/or 5' end of said oligonucleotide, said carrier being selected from the group consisting of: SEQ ID NO: 47-56. 8. The method according to claim 1, wherein said oligonucleotide is at least one molecule of natural nucleic acid, at least one molecule of natural nucleic acid chemically modified, or at least one molecule of synthetic nucleic acid selected from PNA, LNA or morpholino, at least one molecule of synthetic nucleic acid chemically modified or a combination of said natural nucleic acid and said synthetic nucleic acid. 9. The method according to claim 8, wherein said PNA has a modified backbone wherein the alpha carbon has the side chain of arginine or lysine as a substituent. 10. The method according to claim 1, wherein said oligonucleotide is selected among: SEQ ID NO: 2-15, SEQ ID NO: 24, 25. 11. The method according to claim 10, wherein SEQ ID NO: 2-15, 66-69, 24, 25 are directed against the MYCN gene. 12. The method according to claim 10, wherein said oligonucleotide is conjugated at the 5' and/or 3' end with SEQ ID NO: 47. 13. The method according to claim 1, wherein said combination is SEQ ID: NO 1 and carboplatin, or etoposide or cisplatin or vincristine; or SEQ ID: NO 5 and carboplatin, or etoposide or cisplatin or vincristine. 14. The method according to claim 1, wherein the tumor is selected from the group consisting of: neuroblastoma, Wilms' tumor, retinoblastoma and small cell lung cancer. 15. The method according to claim 1, wherein said oligonucleotide is selected from among: SEQ ID NO:70-74 directed against the gene MYC.

Details for Patent 10,752,900

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2032-02-24